1-3 of 3
Stacey M. Bagby
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer

Robert W. Lentz, Tyler J. Friedrich, Patrick J. Blatchford, Kimberly R. Jordan, Todd M. Pitts, Hannah R. Robinson, S. Lindsey Davis, Sunnie S. Kim, Alexis D. Leal, Mathew R. Lee, Meredith R.N. Waring, Anne C. Martin, Adrian T.A. Dominguez, Stacey M. Bagby, Sarah J. Hartman, S. Gail Eckhardt, Wells A. Messersmith, Christopher H. Lieu
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3768–3778.
https://doi.org/10.1158/1078-0432.CCR-24-0090
Published: 03 September 2024
View article titled, A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer
Open the PDF for A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors

S. Lindsey Davis, Anastasia A. Ionkina, Stacey M. Bagby, James D. Orth, Brian Gittleman, Joshua M. Marcus, Elaine T. Lam, Bradley R. Corr, Cindy L. O'Bryant, Ashley E. Glode, Aik-Choon Tan, Jihye Kim, John J. Tentler, Anna Capasso, Kyrie L. Lopez, Daniel L. Gustafson, Wells A. Messersmith, Stephen Leong, S. Gail Eckhardt, Todd M. Pitts, Jennifer R. Diamond
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4633–4642.
https://doi.org/10.1158/1078-0432.CCR-19-3498
Published: 01 September 2020
View article titled, Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors
Open the PDF for Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract PR03: Characterizing the immune context of responses to immunotherapy in humanized patient derived xenograft models of CRC

Anna Capasso, Julie Lang, Todd M. Pitts, S. Lindsey Davis, Chris H. Lieu, Stacey M. Bagby, Aik Choon Tan, John J. Tentler, Jill E. Slansky, Roberta Pelanda, S. Gail Eckhardt
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (16_Supplement): PR03.
https://doi.org/10.1158/1557-3265.PDX16-PR03
Published: 15 August 2016
View article titled, Abstract PR03: Characterizing the immune context of responses to immunotherapy in humanized patient derived xenograft models of CRC